SAFETY Safety will be assessed on the basis of adverse event (AE) reports, including regimen limiting toxicities (RLTs), clinical laboratory data, ECG parameters, physical examinations and vital si gn data. The ITT Population will be used to summarize all safety analyses. All safety data listing s will be presented by patient for all enrolled patient s. 9.1. EXTENT OF EXPOSURE Exposure to study medication will be summarized by providing descriptive statistics for the number of SL-701injections per patient. All extent of exposure summaries will be reported using the ITT Population . The date of administration of SL-701 will be listed by patient by visit. 9.2. TREATMENT COMPLIANCE The number and percentage of SL-701 injections that were administered and the number of complete doses of the regimen will be summarized descriptively... For Stage 1, the total number of complete doses of the regimen received by the patients will also be summarized categorically using the following groupings: 1-2 doses; 3-4; doses; 5-8 doses; 9 -12 doses; > 12 doses. For Stage 2, the total number of complete doses of the regimen received by the patients will be summarized categorically using the following groupings: 1-2 doses; 3-4; doses; 5- 8 doses; 9-12 doses; 13 –16 doses; > 16 doses. For Stage 2, the number of treatments with bevacizumab will be summarized descriptively. The total number of bevacizumab treatments will also be summarized categorically using the following groupings: 1 –4 doses; 5-8 doses; 9-16 doses; 17-24 doses;25-32 doses; > 32 doses. All treatment compliance summaries will be reported using the ITT Population.